Ciproxin HC eardrops application for funding--and response from PHARMAC
Baber, W.J.; Neeff, M.
New Zealand medical journal 121(1281): 111-2; author reply 112-4
2008
ISSN/ISBN: 0028-8446 PMID: 18797496 Document Number: 620781
Document emailed within 1 workday
Related Documents
Milne, R.; Wonder, M. 2011: Response to PHARMAC on Access to new medicines in New Zealand compared to Australia New Zealand Medical Journal 124(1347): 91-93Rutka, J. 2003: Aminoglycoside-containing eardrops: avoiding ototoxicity and choosing safer alternatives Ear Nose and Throat Journal 82(8 Suppl 2: 9-12
Brantley, F. 1991: Funding, survival and growth of postdoctoral general dentistry programs after federal funding ends Journal of Dental Education 55(8): 503-504
Brantley, F. 1991: Funding, survival and growth of postdoctoral general dentistry programs after federal funding ends Journal of Dental Education 55(8): 503-504
Bennett, W.; McNee, W. 1998: PHARMAC and statins New Zealand Medical Journal 111(1077): 439-440
Crampton, P. 2019: The ongoing evolution of capitation funding for primary care: the December 2018 PHO capitation funding changes for Community Services Card holders New Zealand Medical Journal 132(1498): 69-78
Corns, C.A. 1991: The impact of public abortion funding decisions on indigent women: a proposal to reform state statutory and constitutional abortion funding provisions University of Michigan Journal of Law Reform. University of Michigan. Law School 24(2): 371-403
Tabatadze, S.; Gorgadze, N. 2017: School voucher funding system of post-Soviet Georgia: from lack of funding to lack of deliverables Journal of School Choice 12(2): 271-302
Metcalfe, S.; Moodie, P.; Davies, A.; McNee, W.; Dougherty, S. 2005: PHARMAC responds on salbutamol New Zealand Medical Journal 118(1221): U1644
Haddad, P. 1999: PHARMAC complicates treatment of glaucoma New Zealand Medical Journal 112(1099): 434
Grocott, R.; Metcalfe, S.; Moodie, P. 2006: PHARMAC and erythropoietin for cancer patients New Zealand Medical Journal 119(1236): U2039
Metcalfe, S.; Wilkinson, T.; Rasiah, D. 2006: PHARMAC responds on agents to prevent osteoporotic fractures New Zealand Medical Journal 119(1230): U1895
Metcalfe, S.; Moodie, P.; McNee, W. 2005: PHARMAC and tobacco control in New Zealand: two licensed funded options are already available New Zealand medical journal 118(1217): U1544; author reply U1544; discussion U1544
Grocott, R.; Metcalfe, S. 2012: PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metric New Zealand Medical Journal 125(1358): 89-90
Grocott, R.; Metcalfe, S.; Alexander, P.; Werner, R. 2013: Assessing the value for money of pharmaceuticals in new Zealand--PHARMAC's approach to cost-utility analysis New Zealand Medical Journal 126(1378): 60-73
1989: Program announcement, proposed funding categories, proposed review criteria and proposed funding preference for training grants for acquired immunodeficiency syndrome (AIDS) Regional Education and Training Centers Program--HRSA Federal Register 54(119): 26256-26258
Rich, J.R.; Johnson, J.T.; Hodge, C.H. 1985: Corn response to subsoiling and nematicide application Journal of Nematology 17(4): 404-407
Ramfrez Schon, G.; Torres Velázquez, A. 1996: Response of sporotrichosis granuloma to local application of iodine Boletin de la Asociacion Medica de Puerto Rico 88(7-9): 55-56
Murad, F. 1972: Cylic AMP. a mediator of hormone response and its clinical application Virginia Medical Monthly 99(11): 1197-1201
Karpenko, L.I.; Mechetina, L.V.; Reguzova, A.I. 2011: MHC-multimers and their application in studies of antiviral immune response Zhurnal Mikrobiologii Epidemiologii i Immunobiologii 2: 112-119